An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands

In September 2014, the PARADIGM-HF trial showed the heart failure drug combination sacubitril/valsartan to be superior to enalapril for patients with a reduced ejection fraction.

Source: Value in Health - December 21, 2016 Category: Global & Universal Authors: Simon van der Pol, Fabian Degener, Maarten J. Postma, Pepijn Vemer Source Type: research